Cartesian Therapeutics (RNAC) Treasury Shares (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Treasury Shares of $736272.0 for Q1 2026, up 28.58% year-over-year from $572605.0 in Q1 2025, and up 40.91% quarter-over-quarter from $522498.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Treasury Shares (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Treasury Shares for 11 consecutive years, with $736272.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares rose 28.58% year-over-year to $736272.0; the TTM figure through Mar 2026 stood at $736272.0 (up 28.58% YoY), while the FY2025 annual figure was $522498.0, up 17.62% from the prior year.
- Treasury Shares improved to $736272.0 in Q1 2026 per RNAC's latest filing, from $522498.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $2.5 million in Q1 2023 and bottomed at $435120.5 in Q4 2023.
- Historically, Treasury Shares has averaged $1.1 million across 5 years, with a median of $736272.0 in 2026.
- Annual changes were most pronounced in 2022 — Treasury Shares jumped 215.17% — and 2024, when it advanced 2.1%.
- Cartesian Therapeutics' Treasury Shares stood at $1.8 million in 2022, then plunged by 75.43% to $435120.5 in 2023, then grew by 2.1% to $444238.0 in 2024, then increased by 17.62% to $522498.0 in 2025, then surged by 40.91% to $736272.0 in 2026.
- Business Quant data shows RNAC's Treasury Shares at $736272.0 in Q1 2026, $522498.0 in Q4 2025, and $523254.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 648,078.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 648,078.00 |
| Jun 30, 2026 | 648,078.00 |
| Mar 31, 2026 | 736,272.00 |
| Mar 31, 2026 | 736,272.00 |
| Dec 31, 2025 | 522,498.00 |
| Dec 31, 2025 | 522,498.00 |
| Sep 30, 2025 | 523,254.00 |
| Sep 30, 2025 | 523,254.00 |
| Jun 30, 2025 | 533,331.00 |
| Jun 30, 2025 | 533,331.00 |
| Mar 31, 2025 | 572,605.00 |
| Mar 31, 2025 | 572,605.00 |
| Dec 31, 2024 | 444,238.00 |
| Dec 31, 2024 | 444,238.00 |
| Dec 31, 2023 | 435,120.51 |
| Dec 31, 2023 | 435,120.51 |
| Sep 30, 2023 | 2.05 Mn |
| Sep 30, 2023 | 2.05 Mn |
| Jun 30, 2023 | 2.41 Mn |
| Jun 30, 2023 | 2.41 Mn |